Danaher Corporation ($200.53) sits roughly five weeks out from its next scheduled quarterly financial release on October 20, 2026. As that reporting date approaches, consensus among Wall Street desks models a mean price target of $229.09, pointing to an implied upside of 14.2%.
The setup reflects a measured stance across the sell side. Despite a solid consensus rating, Danaher's projected runway currently trails the broader medical equipment and life sciences peer group, positioning the stock slightly below average in near-term implied expansion.
Single-name read
The Street maintains an overarching strong buy consensus on Danaher across 23 covering analysts, but underlying price target revisions reveal a noticeable recalibration over the summer. Following earlier updates, firms trimmed their expectations: Stifel cut its target from $260 to $220, TD Cowen adjusted from $240 to $236, and Wells Fargo reduced its objective from $212 to $195. Even with those reductions, the aggregated target leaves double-digit room above the prevailing $200.53 share price, based on dataset records compiled as of September 11, 2026, at 00:53 UTC.
Valuation metrics highlight the multiple compression analysts are anticipating. Danaher currently trades at a trailing price-to-earnings ratio of 35.75, while its forward P/E stands significantly lower at 21.57. That drop between trailing and forward multiples indicates an expectation of expanding underlying profitability over the coming fiscal periods. Income generation remains secondary to capital deployment here, with the dividend yield registering at 0.78%, while a beta of 0.81 underscores historically lower volatility relative to the wider equity market.
Corporate insider activity shows meaningful aggregate volume on the sell side over recent tracking periods. Records show 10 meaningful insider selling transactions totaling 1,184,978 shares disposed of, with zero recorded open-market purchases. While executive dispositions often occur under pre-arranged trading schedules or tax plans, the imbalance is substantial enough to contrast against the buy-side sentiment maintained by brokerage analysts.
Context from peers
Within the wider peer universe detailed on the Healthcare sector page, Danaher occupies the 11th rank in projected target appreciation. The collective sector average upside sits at 15.0%, putting Danaher’s 14.2% figure slightly under the broad median.
The variance becomes clearer when examining high-beta medical device and diagnostics peers tracked in the same cohort. Boston Scientific (BSX), for instance, carries a consensus implied upside of 45.5%, leading the group by a wide margin. Other key sector components show elevated target bands as well: Stryker (SYK) screens with 39.9% implied upside, and Intuitive Surgical (ISRG) posts a 32.6% consensus margin.
That spread matters because it demonstrates where Wall Street sees the most aggressive re-rating potential within healthcare. While Danaher retains wide institutional backing with its 23 analyst coverage pool and strong buy consensus, the Street’s models assign far more conservative appreciation parameters to DHR than to high-growth surgical and device peers. The coming October earnings report will serve as the primary test for whether forward earnings expectations can spark upward revisions to Danaher's target band.